2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
United States
781 552 4452
https://www.bonebiologics.com
Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 2
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Jeffrey Frelick | CEO & President | 325k | N/A | 1966 |
Ms. Deina H. Walsh | Chief Financial Officer | 212,5k | N/A | 1964 |
Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Bone Biologics Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.